Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 157

1.

Farnesyl transferase inhibitors for patients with lung cancer.

Johnson BE, Heymach JV.

Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4254s-4257s. Review.

PMID:
15217969
[PubMed - indexed for MEDLINE]
Free Article
2.

Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer.

Adjei AA, Mauer A, Bruzek L, Marks RS, Hillman S, Geyer S, Hanson LJ, Wright JJ, Erlichman C, Kaufmann SH, Vokes EE.

J Clin Oncol. 2003 May 1;21(9):1760-6.

PMID:
12721252
[PubMed - indexed for MEDLINE]
3.

Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer.

Heymach JV, Johnson DH, Khuri FR, Safran H, Schlabach LL, Yunus F, DeVore RF 3rd, De Porre PM, Richards HM, Jia X, Zhang S, Johnson BE.

Ann Oncol. 2004 Aug;15(8):1187-93.

PMID:
15277257
[PubMed - indexed for MEDLINE]
Free Article
4.

Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.

Caponigro F.

Anticancer Drugs. 2002 Sep;13(8):891-7.

PMID:
12394276
[PubMed - indexed for MEDLINE]
5.

Farnesyl transferase inhibitors in the treatment of breast cancer.

Kelland LR.

Expert Opin Investig Drugs. 2003 Mar;12(3):413-21. Review.

PMID:
12605564
[PubMed - indexed for MEDLINE]
6.

Farnesyl transferase inhibitors as anticancer agents.

Haluska P, Dy GK, Adjei AA.

Eur J Cancer. 2002 Sep;38(13):1685-700. Review.

PMID:
12175684
[PubMed - indexed for MEDLINE]
7.

Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.

End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, Venet M, Sanz G, Poignet H, Skrzat S, Devine A, Wouters W, Bowden C.

Cancer Res. 2001 Jan 1;61(1):131-7.

PMID:
11196150
[PubMed - indexed for MEDLINE]
Free Article
8.

Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies.

Karp JE.

Semin Hematol. 2001 Jul;38(3 Suppl 7):16-23. Review.

PMID:
11523024
[PubMed - indexed for MEDLINE]
9.

Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action.

Jabbour E, Kantarjian H, Cortes J.

Leuk Lymphoma. 2004 Nov;45(11):2187-95. Review.

PMID:
15512806
[PubMed - indexed for MEDLINE]
10.

Farnesyl transferase inhibitors in clinical development.

Caponigro F, Casale M, Bryce J.

Expert Opin Investig Drugs. 2003 Jun;12(6):943-54. Review.

PMID:
12783599
[PubMed - indexed for MEDLINE]
11.

An overview of farnesyltransferase inhibitors and their role in lung cancer therapy.

Adjei AA.

Lung Cancer. 2003 Aug;41 Suppl 1:S55-62. Review.

PMID:
12867063
[PubMed - indexed for MEDLINE]
12.

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.

Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K, Horak I, Tidwell ML, Liesveld J, Kottke TJ, Ange D, Buddharaju L, Gojo I, Highsmith WE, Belly RT, Hohl RJ, Rybak ME, Thibault A, Rosenblatt J.

Blood. 2001 Jun 1;97(11):3361-9.

PMID:
11369625
[PubMed - indexed for MEDLINE]
Free Article
13.

In vitro study of farnesyltransferase inhibitor SCH 66336, in combination with chemotherapy and radiation, in non-small cell lung cancer cell lines.

Loprevite M, Favoni RE, De Cupis A, Scolaro T, Semino C, Mazzanti P, Ardizzoni A.

Oncol Rep. 2004 Feb;11(2):407-14.

PMID:
14719076
[PubMed - indexed for MEDLINE]
14.

Effects of statins and farnesyl transferase inhibitors on ERK phosphorylation, apoptosis and cell viability in non-small lung cancer cells.

Pelaia G, Gallelli L, Renda T, Fratto D, Falcone D, Caraglia M, Busceti MT, Terracciano R, Vatrella A, Maselli R, Savino R.

Cell Prolif. 2012 Dec;45(6):557-65. doi: 10.1111/j.1365-2184.2012.00846.x. Epub 2012 Oct 10.

PMID:
23045963
[PubMed - indexed for MEDLINE]
15.

Farnesyl protein transferase inhibitors as potential cancer chemopreventives.

Kelloff GJ, Lubet RA, Fay JR, Steele VE, Boone CW, Crowell JA, Sigman CC.

Cancer Epidemiol Biomarkers Prev. 1997 Apr;6(4):267-82. Review.

PMID:
9107432
[PubMed - indexed for MEDLINE]
Free Article
16.

Farnesyl transferase inhibitors: the next targeted therapies for breast cancer?

O'Regan RM, Khuri FR.

Endocr Relat Cancer. 2004 Jun;11(2):191-205. Review.

PMID:
15163298
[PubMed - indexed for MEDLINE]
Free Article
17.

Effect of farnesyl transferase inhibitor R115777 on the growth of fresh and cloned myeloma cells in vitro.

Ochiai N, Uchida R, Fuchida S, Okano A, Okamoto M, Ashihara E, Inaba T, Fujita N, Matsubara H, Shimazaki C.

Blood. 2003 Nov 1;102(9):3349-53. Epub 2003 Jul 3.

PMID:
12842991
[PubMed - indexed for MEDLINE]
Free Article
18.

Farnesyl transferase inhibitors in myeloid malignancies.

Lancet JE, Karp JE.

Blood Rev. 2003 Sep;17(3):123-9. Review.

PMID:
12818222
[PubMed - indexed for MEDLINE]
19.

Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer.

Kelland LR, Smith V, Valenti M, Patterson L, Clarke PA, Detre S, End D, Howes AJ, Dowsett M, Workman P, Johnston SR.

Clin Cancer Res. 2001 Nov;7(11):3544-50.

PMID:
11705875
[PubMed - indexed for MEDLINE]
Free Article
20.

Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.

Cohen SJ, Ho L, Ranganathan S, Abbruzzese JL, Alpaugh RK, Beard M, Lewis NL, McLaughlin S, Rogatko A, Perez-Ruixo JJ, Thistle AM, Verhaeghe T, Wang H, Weiner LM, Wright JJ, Hudes GR, Meropol NJ.

J Clin Oncol. 2003 Apr 1;21(7):1301-6.

PMID:
12663718
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk